The board of Directors in its meeting held on Thursday, July 31, 2025 approved the Un-audited Standalone Financial Results of the Company for the First Quarter ended on June 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts less than Nifty Microcap 250 and 4.5 pts less than its Software Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hindustan Bio Sciences Ltd reported weak Q1FY26 results with revenue from operations falling to ₹32.19 lakhs from ₹41.11 lakhs in the same quarter last year, a drop of about 22%. Net profit plunged to ₹1.40 lakhs from ₹8.18 lakhs, an 83% decline year-on-year, dragging EPS down to ₹0.01 from ₹0.08. The company's reserves remain negative at ₹114.52 lakhs, indicating accumulated losses on the balance sheet. The auditor (VASG & Associates) gave an unmodified limited review opinion on the numbers. The Board also accepted the resignation of Company Secretary Mr. Devanshu Ravinder Dange due to personal reasons and appointed Mr. Shailendra Vyas in his place effective August 1, 2025. The 33rd Annual General Meeting has been scheduled for September.
Sharp year-on-year fall in both revenue and profit, combined with already negative reserves, signals continued stress on the business with little cushion for shareholders. Routine KMP (Company Secretary) change is a procedural item and not a governance red flag on its own.